Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications.
BACKGROUND
A biomarker that reliably detects myocardial ischemia in the absence of necrosis would be useful for initial identification of unstable angina patients and for differentiating patients with chest pain of an etiology other than coronary ischemia, and could provide clinical utility complementary to that of cardiac troponins, the established markers of necrosis. Unbound free fatty acids (FFA(u)) and their intracellular binding protein, heart-type fatty acid-binding protein (H-FABP), have been suggested to have clinical utility as indicators of cardiac ischemia and necrosis, respectively.


METHODS
We examined results of clinical assessments of FFA(u) and H-FABP as biomarkers of cardiac ischemia and necrosis. Data published on FFA(u) and H-FABP over the past 30 years were used as the basis for this review.


RESULTS
Although little clinical work has been done on FFA(u) since the initial reports, recent studies documented an association between increased serum FFAs and ventricular dysrhythmias and death in patients with acute myocardial infarction (AMI). Recent data suggest that serum FFA(u) concentrations increase well before markers of cardiac necrosis and are sensitive indicators of ischemia in AMI. H-FABP is abundant in cardiac muscle and is presumed to be involved in myocardial lipid homeostasis. Similar to myoglobin, plasma H-FABP increases within 3 h after AMI and returns to reference values within 12-24 h.


CONCLUSIONS
FFA(u) may have a potential role in identifying patients with cardiac ischemia. H-FABP is useful for detecting cardiac injury in acute coronary syndromes and predicting recurrent cardiac events in acute coronary syndromes and in congestive heart failure patients. Assays are available for both markers that could facilitate further clinical investigations to assess their possible roles as markers of cardiac ischemia and/or necrosis.
Azzazy
Hassan M E
HM
Department of Chemistry and Science & Technology Research Center, School of Science and Engineering, The American University in Cairo, Cairo, Egypt. hazzazy@aucegypt.edu
Pelsers
Maurice M A L
MM
Christenson
Robert H
RH
D015415:Biomarkers / Q000097:blood; D001798:Blood Proteins / Q000378:metabolism*; D050556:Fatty Acid-Binding Proteins / Q000097:blood* / Q000378:metabolism; D005230:Fatty Acids, Nonesterified / Q000097:blood* / Q000378:metabolism; D006333:Heart Failure / Q000175:diagnosis / Q000209:etiology; D006801:Humans; D007118:Immunoassay; D009203:Myocardial Infarction / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology; D017202:Myocardial Ischemia / Q000150:complications / Q000175:diagnosis* / Q000473:pathology; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D009336:Necrosis; D011237:Predictive Value of Tests; D011379:Prognosis; D011485:Protein Binding; D012008:Recurrence; D013997:Time Factors
D015415:Biomarkers; D001798:Blood Proteins; D050556:Fatty Acid-Binding Proteins; D005230:Fatty Acids, Nonesterified